Clinical Trial Update: Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating DA-EPOCH chemotherapy with or without rituximab, in combination with tafasitamab, for newly diagnosed Philadelphia chromosome-nega…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-negative B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DA-EPOCH chemotherapy regimen
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• Monjuvi (tafasitamab)
• PREDNISONE (Prednisone)
• Rituxan (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: University of Washington | Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 | Status: RECRUITING